Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ONgoing Telmisartan Alone or in combination with Ramipril Global Endpoint Trial.

Trial Profile

ONgoing Telmisartan Alone or in combination with Ramipril Global Endpoint Trial.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Telmisartan (Primary) ; Ramipril
  • Indications Angina pectoris; Cardiovascular disorders; Heart failure; Hypertension; Intermittent claudication; Left ventricular hypertrophy; Myocardial infarction; Stroke; Unstable angina pectoris
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms ONTARGET
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 01 Feb 2013 Results published in the Journal of Hypertension.
    • 31 Aug 2011 Patient adherence results presented at the ESC Congress 2011: Annual Congress of the European Society of Cardiology.
    • 30 Aug 2010 A late-breaking analysis reviewing 21 trials, including ONTARGET, was presented at the European Society of Cardiology (ESC) Congress, according to a European Society of Cardiology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top